Insider Trading June 5, 2026 05:13 PM

Live Oak Bancshares CEO James Mahan III Executes $737k Stock Sale Under Pre-Arranged Plan

Insider transaction details reveal structured selling activity alongside recent earnings beat and dividend announcements.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
LOB

James S. Mahan III, the Chief Executive Officer and a significant shareholder of Live Oak Bancshares, Inc. (NASDAQ: LOB), has executed a series of stock sales totaling approximately $737,302. The transactions, conducted through a Rule 10b5-1 trading plan established in August 2025, involved the liquidation of 20,000 shares across early June 2026. This insider activity occurs against a backdrop of recent financial reporting that showed an earnings per share beat but a revenue miss, alongside the declaration of new cash dividends for shareholders.

Live Oak Bancshares CEO James Mahan III Executes $737k Stock Sale Under Pre-Arranged Plan
LOB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO James S. Mahan III executed a $737,302 stock sale through a pre-arranged Rule 10b5-1 plan, liquidating 20,000 shares across June 3 and June 4, 2026.
  • Live Oak Bancshares reported a Q1 2026 EPS beat of $0.60 versus $0.59 expectations, but fell short on revenue with $145.47 million reported against $151.23 million anticipated.
  • The company declared new cash dividends, paying $0.03 per common share and $0.52344 per preferred share, with payment scheduled for June 15, 2026.

James S. Mahan III, serving as Chief Executive Officer, Director, and a ten percent owner of Live Oak Bancshares, Inc. (NASDAQ: LOB), has completed a structured sale of company equity. The executive and his affiliated trusts disposed of 20,000 shares of common stock across two trading days in early June 2026. The total value of these transactions reached approximately $737,302, executed at share prices fluctuating between $36.4212 and $37.65.

The sales were not ad hoc but were conducted indirectly through the James S. Mahan Revocable Trust. This activity was governed by a Rule 10b5-1 trading plan that was formally adopted on August 27, 2025. The use of such a plan typically indicates pre-arranged selling parameters set prior to the initiation of any material non-public information regarding the sale dates.

Market analysis from InvestingPro currently positions Live Oak Bancshares at a price-to-earnings (P/E) ratio of 20.5. Despite this valuation multiple, the analysis suggests the stock remains undervalued when measured against its calculated Fair Value. Over the trailing twelve months, the stock has generated a 38% return for investors.

The transaction timeline reveals a granular breakdown of the liquidation. On June 3, 2026, the trust initiated sales by offloading 9,363 shares. These specific shares traded at a weighted average price of $36.4212, with individual transaction prices ranging from $36.01 to $36.90. Later that same day, an additional 637 shares were liquidated at a weighted average price of $37.1419, with execution prices falling between $37.13 and $37.28.

Activity continued on June 4, 2026. The trust sold 9,921 shares at a weighted average price of $37.2601, with trades executing between $36.64 and $37.61. A final block of 79 shares was sold on this date at a fixed price of $37.65 per share.

Following these liquidations, the James S. Mahan Revocable Trust retains a significant position, holding 2,867,844 shares of Live Oak Bancshares Voting Common Stock. Mr. Mahan maintains indirect beneficial ownership across a broader portfolio of trusts and entities. This includes 3,032,547 shares held by the Marguerite D. Mahan Revocable Trust, 127,167 shares via the 2021 Chip Mahan Family and Charitable Trust, another 127,167 shares through the 2021 Peggy Mahan Family Trust, and 140,150 shares controlled by Peapod II, LLC.

In recent corporate developments, Live Oak Bancshares reported its first quarter of 2026 earnings. The company achieved an earnings per share (EPS) of $0.60, surpassing analyst consensus estimates of $0.59. However, top-line performance did not meet expectations, with revenue reported at $145.47 million against anticipated figures of $151.23 million.

Concurrently, the company announced the declaration of cash dividends for both common and preferred share classes. The common share dividend is set at $0.03 per share, while the preferred share dividend is established at $0.52344 per share. These distributions are scheduled for payment on June 15, 2026, to shareholders of record as of June 2, 2026.

Corporate governance updates also occurred during the 2026 Annual Meeting of Shareholders. Shareholders voted on several key proposals, including the election of ten directors. Among those elected to one-year terms were Tonya W. Bradford and William H. Cameron. The meeting also saw shareholder approval of equity plans and executive compensation structures, signaling alignment on strategic governance frameworks.

Risks

  • Revenue shortfall in Q1 2026 indicates potential pressure on top-line growth, impacting the financial sector's valuation metrics.
  • Insider selling activity, while pre-arranged, may signal liquidity needs or portfolio rebalancing that warrants monitoring for market sentiment shifts.

More from Insider Trading

Rocket Lab Director Slusky Offloads $4.94M in Equity Amid Sector Valuation Debate Jun 5, 2026 Xeris Biopharma Director Marla Persky Executes Strategic Share Transactions Amidst Financial Momentum Jun 5, 2026 Getty Images Executive Offloads Shares Amidst Merger Uncertainty and Earnings Miss Jun 5, 2026 Datadog Director Dev Ittycheria Offloads $34.3 Million in Shares Amid Strong Stock Performance Jun 5, 2026 Xeris Biopharma Director John Johnson Executes Share Transactions Amidst Strong Quarterly Performance Jun 5, 2026